Muparfostat
As of the edition of 20 October 2026, Muparfostat is a drug: stopped in 2015; acts on FGF1, FGF2 and HPSE and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2015
- Kind
- Unknown
- Registered trials
- 9, 2 stopped early
- Disease areas
- Cancer; Digestive system; Skin and connective tissue; Lungs and airways; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
8 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product8 company-target rows are on route A because of Muparfostat.
See the 8 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 7 | 7 | 0 | 0 |
| Phase 3 | 2 | 0 | 0 | 2 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Cellxpert Biotechnology | Lead sponsor of trials | 2001 to now |
| Progen Pharmaceuticals | Lead sponsor of trials | 2005 to now |